Practical lifestyle interventions are needed to help people with type 2 diabetes increase their physical activity and follow nutrition therapy guidelines. This study examined whether combining instructions to walk more and to eat more low-glycemic index (GI) foods (First Step First Bite Program) improved hemoglobin A1c and anthropometric and cardiovascular health outcomes in people with type 2 diabetes vs the First Step Program (instruction only on walking). Subjects were randomly assigned to the First Step Program or First Step First Bite Program (n=22 in each group) and attended four weekly group meetings with minimal follow-up during weeks 5 to 16. All subjects monitored steps per day throughout the study; First Step First Bite Program subjects also monitored daily intake of low-GI foods. At week 16 (n=19 per group), both groups had increased steps per day by approximately 3,000 compared with baseline (P<0.01). In the First Step Program vs First Step First Bite Program groups, respectively, waist girth decreased by 5.9+/-0.9 cm vs 3.7+/-0.5 cm and hip decreased by 3.7+/-0.6 cm vs 2.2+/-0.5 cm (P<0.01 over time, both groups). There was no significant difference between groups at week 16 for anthropometric or metabolic variables measured, including hemoglobin A1c. Both the First Step First Bite Program and First Step Program resulted in increased physical activity; First Step First Bite Program also increased daily intake of low-GI foods. Both groups experienced similar significant reductions in waist and hip girth. Thus, adding a low-GI component to a walking program in people with type 2 diabetes in good glycemic control did not improve anthropometric or metabolic outcomes. A great number and/or longer duration of low-GI foods may be required to observe improved clinical outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jada.2009.05.012 | DOI Listing |
J Med Life
October 2024
Department of Removable Prosthodontics, Faculty of Dental Medicine, University of Monastir, Monastir, Tunisia.
Amelogenesis imperfecta refers to a group of hereditary diseases that affect dental enamel, often leading to a wide range of clinical manifestations and aesthetic concerns. This case report describes a female patient diagnosed with amelogenesis imperfecta associated with a skeletal open bite. The treatment approach was multidisciplinary.
View Article and Find Full Text PDFMedicina (B Aires)
December 2024
Departamento de Bacteriología, Servicio Bacteriología Especial, INEI-ANLIS Carlos G. Mabrán, Buenos Aires, Argentina.
Sci Justice
November 2024
Forensic Research Institute, Liverpool John Moores University, Byrom Street, Liverpool, UK; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK.
The absence of a standardised method to quantify canine DNA recovered from livestock attacks leaves forensic providers without an important quality control step to help support their decision making. Typically used to normalise the amount of DNA for STR amplification, modern forensic DNA quantification approaches use qPCR of target genes and can also include an Internal Positive Controls (IPC) to determine the presence of PCR inhibitors. The co-amplification of livestock DNA alongside canine DNA has meant that previously developed qPCR methods are not suitable for use so a standardised approach is needed.
View Article and Find Full Text PDFNanoscale
January 2025
Shandong Laboratory of Advanced Materials and Green Manufacturing at Yantai, Yantai, 264006, China.
Two-dimensional (2D) nanomaterials have attracted much attention for the lubrication enhancement of water. Stably dispersing nanosheets in water for an extended period is a challenging task. 2D montmorillonite (MMT) nanosheets are modified with protonic ionic liquids (PILs) with the assistance of simple and efficient mechanochemical synthesis, which can stably disperse in water.
View Article and Find Full Text PDFClin Pharmacokinet
December 2024
Clinical Pharmacology Modeling & Simulation, Amgen, Thousand Oaks, CA, USA.
Background: Tarlatamab binds to delta-like ligand 3 on cancer cells and cluster of differentiation-3 on T cells, leading to T-cell-mediated tumor lysis, and has demonstrated a promising safety and efficacy profile in patients with previously treated small-cell lung cancer (SCLC). Here, we present pharmacokinetic results from DeLLphi-300 (NCT03319940), an ongoing international, open-label, first-in-human study in previously treated adult patients with SCLC.
Methods: Multiple escalating doses of tarlatamab were administered every 2 weeks (Q2W; 0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!